News of Note—Meissa’s chairman from J&J, Takeda and more

non
In this week's news of note, Meissa named a former Johnson & Johnson executive as chairman. (Pixabay)

Here's some other vaccine news of note for the week.

> Meissa Vaccines named Lawrence Blatt, Ph.D., Johnson & Johnson’s recent global head of infectious diseases and vaccines, as its chairman. Release

Takeda established a Center of Excellence in Singapore for vaccine development. It will hire and train local talent to work on the company's current and future vaccine candidates. Asian Scientist article

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> An American expert told the Philippine Senate that he warned Sanofi on the health risks of Dengvaxia in 2016. The Manila Times article

PharmaJet is close to completing a $5 million financing round to fund the production of 5 million syringes to deliver the polio vaccine. MedCity News article

Valneva started a phase 1 study on its live-attenuated, single-dose vaccine candidate against Chikungunya. Release

> Researchers from Cardiff University have created the world’s first synthetic flu vaccine, which is given orally and is stable at room temperature. Cardiff University article

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.